Inclusion Criteria:

• Age > 18 years. Histologically and/or cytologically documented cancer for which carbo-taxol has been determined an appropriate therapy, per Investigator.
• Measurable disease by CT or MRI as defined RECIST. Subjects with brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of CNS disease progression as determined by CT or MRI within 28 days prior to the 1st dose of study drug.
• ECOG < 1.

• Must have adequate bone marrow, renal and hepatic function per local laboratory reference range as follows:

  • Bone marrow:Absolute Neutrophil Count≥1500/μL
  • Platelets ≥ 150,000/mm3
  • Hemoglobin ≥ 9.0 g/dL
• Renal function: Serum creatinine ≤ 1.2 mg/dL or calculated creatinine clearance ≥ 50 mL/min

• Hepatic function and enzymes:

  • AST
  • ALP and ALT ≤ 3.0 × the upper limit of normal (ULN)
  • Bilirubin ≤ 1.25 × ULN.
• Subjects with liver metastasis may have AST, ALP, and ALT less then or equal to 5.0 X ULN.
• Subjects with bone metastasis may have ALP ≤ 5.0 × ULN;
• Coagulation: aPTT and PT not to exceed 1.2 × ULN.
• Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or have negative results for a pregnancy test performed as follows: at Screening via serum sample obtained within 14 days prior to initial study drug administration and prior to dosing via urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.
• Female subjects not surgically sterile or postmenopausal (for at least 1 year) and non-vasectomized male subjects must practice at least 1 of the following methods of birth control: total abstinence from sexual intercourse (minimum 1 complete menstrual cycle); vasectomized partner; hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration; Double-barrier method (including condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream).

Exclusion Criteria:

• Predisposing condition/currently exhibits signs of bleeding.
• Recent history of thrombocytopenia associated with bleeding.
• Currently receiving/requires anticoagulation therapy/any drugs/herbal supplements that affect platelet function, w/the exception of low-dose anticoagulation medications that are used to maintain the patency of a central iv catheter.
• Active peptic ulcer disease/ other potentially hemorrhagic esophagitis/gastritis.
• Active immune thrombocytopenic purpura, autoimmune hemolytic anemia or a history of being refractory to platelet transfusions (w/i 1 year of 1st dose of study drug).
• Received radio-immunotherapy w/i 6 months of 1st dose of study drug. Received antibody therapy or other biologics (with the exception of colony stimulating factors or erythropoietin) w/i 28 days of 1st dose of study drug.
• Received anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal therapy (with some exceptions), or any investigational therapy w/i 14 days of the 1st dose of study drug, or has not recovered to less than a grade 2 clinically significant adverse effect(s)/ toxicity(s) of the previous therapy.
• Received steroid therapy for anti-neoplastic intent w/i 7 days of the 1st dose of study drug (Inhaled steroids for asthma, topical steroids, replacement/stress corticosteroids, or corticosteroids taken as premedication are allowed).
• Received aspirin w/i 7 days of 1st dose of study drug. History of hypersensitivity to Taxol or severe allergic reactions to cisplatin or other platinum-containing compounds.
• Positive for HIV. Significant history of cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.

• Exhibits evidence of other clinically significant uncontrolled condition; active systemic fungal infection;diagnosis of fever & neutropenia w/i

  1 week of study drug administration.

• A history of other active malignancies within the past 3 years prior to screening, with the exception of: adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma of the skin: Previous malignancy confined and surgically resected with curative intent.